Technology insight:: Calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease

被引:56
|
作者
Lundberg, J [1 ]
Hellström, PM
Fagerhol, MK
Weitzberg, E
Roseth, AG
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden
[2] Ullevaal Univ Hosp, Oslo, Norway
[3] Aker Univ Hosp, Oslo, Norway
关键词
calprotectin; fecal marker; inflammatory bowel disease; lactoferrin; nitric oxide;
D O I
10.1038/ncpgasthep0094
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Distinguishing patients with inflammatory bowel disease from those with irritable bowel syndrome can be difficult. A simple and reliable test that detects intestinal inflammation would therefore be very useful in the clinic. If such a test parameter correlated with the intensity of the inflammatory reaction it could also be used to monitor disease activity. Calprotectin, lactoferrin and nitric oxide are produced and released locally in much greater quantities in the inflamed gut than in the noninflamed gut. These compounds can be readily measured in fecal samples (calprotectin and lactoferrin) or directly in the intestinal lumen (nitric oxide gas). Here, we discuss what is known about these markers, how they could be used in clinical practice and how they can complement existing techniques used for the diagnosis and monitoring of inflammatory bowel disease.
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [1] Technology Insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease
    Jon O Lundberg
    Per M Hellström
    Magne K Fagerhol
    Eddie Weitzberg
    Arne G Roseth
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 : 96 - 102
  • [2] Fecal Calprotectin and Lactoferrin as Noninvasive Markers of Pediatric Inflammatory Bowel Disease
    Joishy, Manohara
    Davies, Ieuan
    Ahmed, Mansoor
    Wassel, Julie
    Davies, Karen
    Sayers, Adrian
    Jenkins, Huw
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2009, 48 (01): : 48 - 54
  • [3] Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease
    Caccaro, Roberta
    D'Inca, Renata
    Sturniolo, Giacomo Carlo
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (04) : 551 - 558
  • [4] Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease
    Reinders, Claudia I.
    Jonkers, Daisy
    Jansson, Emmelie A.
    Stockbruegger, Reinhold W.
    Stobberingh, Ellen E.
    Hellstroem, Per M.
    Lundberg, Jon O.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (10) : 1151 - 1157
  • [5] Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease
    Lamb, C. A.
    Mansfield, J. C.
    FRONTLINE GASTROENTEROLOGY, 2011, 2 (01) : 13 - 18
  • [6] Faecal Calprotectin and Lactoferrin for the Prediction of Inflammatory Bowel Disease Relapse
    Gisbert, Javier P.
    GASTROENTEROLOGY, 2009, 136 (05) : A205 - A205
  • [7] Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease?
    Johnson, Lisa M.
    White, Sandra K.
    Schmidt, Robert L.
    CLINICA CHIMICA ACTA, 2020, 510 : 191 - 195
  • [8] Fecal Calprotectin and Lactoferrin for the Prediction of Inflammatory Bowel Disease Relapse
    Gisbert, Javier P.
    Bermejo, Fernando
    Perez-Calle, Jose-Lazaro
    Taxonera, Carlos
    Vera, Isabel
    McNicholl, Adrian G.
    Algaba, Alicia
    Lopez, Pilar
    Lopez-Palacios, Natalia
    Calvo, Marta
    Gonzalez-Lama, Yago
    Carneros, Jose-Antonio
    Velasco, Marta
    Mate, Jose
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (08) : 1190 - 1198
  • [9] Nitric oxide and inflammatory bowel disease
    Rabinowitz, SS
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1998, 27 (03): : 372 - 373
  • [10] Nitric oxide in inflammatory bowel disease
    Cross, RK
    Wilson, KT
    INFLAMMATORY BOWEL DISEASES, 2003, 9 (03) : 179 - 189